Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler’s pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape.Prescription & OTC DrugsOur pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation.Infectious Disease TreatmentsSterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases.Generic Drug DevelopmentWe work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Firm News

September 11, 2026

Sterne Kessler and Director Eldora Ellison Receive Top Awards at 2026 Life Sciences Americas Awards

Sterne, Kessler, Goldstein & Fox

In the News

September 3, 2026

Growth of Clinical Trials, Lawsuits Spotlight Cannabis IP Divide

Bloomberg Law

Articles

August 27, 2026

China-Origin Biotech Assets and the Hidden Question of IP Ownership

Life Sciences Intellectual Property Review